Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs.
The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.
Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis.
The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins.
It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -3.95 Decreased by -2.10 K% | -0.12 Decreased by -3.20 K% |
| Mar 29, 24 | -3.70 Decreased by -3.26 K% | -0.12 Decreased by -2.98 K% |
| Nov 15, 23 | 0.04 Increased by +130.77% | -0.11 Increased by +136.36% |
| Aug 10, 23 | 0.05 Increased by +135.71% | -0.16 Increased by +131.25% |
| May 10, 23 | -0.18 Decreased by -157.14% | -0.14 Decreased by -28.57% |
| Mar 29, 23 | -0.11 Increased by +15.38% | -0.23 Increased by +52.17% |
| Nov 2, 22 | -0.13 Increased by +45.83% | -0.16 Increased by +18.75% |
| Aug 4, 22 | -0.14 Increased by +44.00% | -0.11 Decreased by -27.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 19.52 M Increased by +263.50% | -10.75 M Decreased by -26.03% | Decreased by -55.08% Increased by +65.33% |
| Jun 30, 23 | 20.05 M Increased by +442.32% | 3.98 M Increased by +142.31% | Increased by +19.83% Increased by +107.80% |
| Mar 31, 23 | 1.94 M Decreased by -82.38% | -12.31 M Decreased by -348.52% | Decreased by -635.95% Decreased by -2.45 K% |
| Dec 31, 22 | 5.85 M Decreased by -30.76% | -8.08 M Increased by +11.83% | Decreased by -138.15% Decreased by -27.33% |
| Sep 30, 22 | 5.37 M Increased by +32.36% | -8.53 M Increased by +48.41% | Decreased by -158.86% Increased by +61.02% |
| Jun 30, 22 | 3.70 M Increased by +12.57% | -9.40 M Increased by +39.36% | Decreased by -254.14% Increased by +46.13% |
| Mar 31, 22 | 10.99 M Decreased by -29.71% | -2.75 M Increased by +34.20% | Decreased by -24.98% Increased by +6.39% |
| Dec 31, 21 | 8.44 M Increased by +349.81% | -9.16 M Increased by +36.39% | Decreased by -108.49% Increased by +85.86% |